BiohavenBHVN
About: Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Employees: 256
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
304% more call options, than puts
Call options by funds: $30.7M | Put options by funds: $7.59M
24% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 37
24% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 76
2% more funds holding
Funds holding: 253 [Q4 2024] → 259 (+6) [Q1 2025]
3.46% less ownership
Funds ownership: 91.26% [Q4 2024] → 87.8% (-3.46%) [Q1 2025]
22% less funds holding in top 10
Funds holding in top 10: 9 [Q4 2024] → 7 (-2) [Q1 2025]
37% less capital invested
Capital invested by funds: $3.48B [Q4 2024] → $2.2B (-$1.28B) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
JP Morgan Tessa Romero | 288%upside $55 | Overweight Maintained | 18 Jun 2025 |
RBC Capital Leonid Timashev | 48%upside $21 | Sector Perform Downgraded | 19 May 2025 |
Baird Brian Skorney | 302%upside $57 | Outperform Maintained | 28 Apr 2025 |
Financial journalist opinion
Based on 5 articles about BHVN published over the past 30 days
